Quantcast

North America

Mereo BioPharma’s phase two study of setrusubab misses primary goal

Mereo BioPharma Group’s Phase 2b dose-ranging “Asteroid” clinical study of setrusumab (BPS-804), an anti-sclerostin antibody,  in adults with Type I,

Posted in news, North America | Leave a comment

Scynexis confident in ibrexafungerp’s regulatory and commercial success

Scynexis biotechnology company on Thursday announced positive top-line results for its Phase 3 VANISH-303 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC).

Posted in news, North America | Tagged , | Leave a comment

HLS Therapeutics expects Vatespa to transform business

HLS Therapeutics posted $1.9 million net loss in the third quarter 2019, compared to the same period last year, when it was compared to net loss of $19.7 million, boosted by Canadian-based clozaril sales in the last day of Q2.

Posted in news, North America | Tagged | Leave a comment

Entrome, MSK to work on gut microbiome-derived antigens

Entrome SA, a clinical-stage biopharmaceutical company will work with Memorial Sloan Kettering Cancer Center (MSK) in New York City to evaluate the potential of gut microbiome-derived antigens for development as cancer immunotherapies.

Posted in news, North America | Tagged , | Leave a comment

Sandoz bags FDA’s approval for long-acting oncology supportive care biosimilar Ziextenzo

Sandoz Tuesday said it got approval from US Food and Drug Administration for its biosimilar Ziextenzo, which is in particularly significant since Sandoz short-acting filgrastim Zarxio is the first biosimilar to surpass its reference biologic in US market share.

Posted in news, North America | Tagged , | Leave a comment

4D pharma, Merck get confirmation for its Keytruda MRx0518 combo study

4D pharma Wednesday said that its clinical study with Merck to test MRx0518 combined with Keytruda further support its continued investment into our oncology franchise.

Posted in news, North America | Tagged , , | Leave a comment

Biogen, Alkermes get approval for Vumerity in USA, to treat relapsing forms of MS

Biogen and Alkermes got approval from USFDA for Vumertiy, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

Posted in news, North America | Tagged , , , | Leave a comment

Amgen recenues drop 3% in Q3 2019

Amgen said in a press release Tuesday it’s total revenues decreased 3% to $5.7 billion compared with the same period last year, reflecting the impact of biosimilar and generic competition against key products.

Posted in news, North America | Tagged | Leave a comment

Q-linea positive FDA feedback for planned trial with ASTar in USA

Q-linea AB has received the official response including a number of clarifications and very positive feedback from the US Food and Drug Administration, FDA, regarding the company’s planned pivotal clinical trial with ASTar in the United States.

Posted in news, North America | Tagged , | Leave a comment

Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to

Posted in news, North America | Tagged | Leave a comment